Skip to main content
NOVOGENE CO., LTD. logo

NOVOGENE CO., LTD. — Investor Relations & Filings

Ticker · 688315 ISIN · CNE1000052X3 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 558 across all filing types
Latest filing 2023-04-12 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688315

About NOVOGENE CO., LTD.

https://www.novogene.com

Novogene Co., Ltd. is a global provider of genomic services and solutions, specializing in next-generation sequencing (NGS) and bioinformatics analysis. The company offers a comprehensive suite of services, including whole genome sequencing, transcriptomics, epigenomics, and metagenomics, alongside specialized solutions for single-cell analysis and clinical diagnostics. Utilizing advanced high-throughput sequencing platforms and proprietary bioinformatics pipelines, Novogene supports research across diverse fields such as human health, agriculture, and environmental science. The organization serves a broad client base encompassing academic institutions, pharmaceutical companies, and biotechnology firms. With a focus on data quality and technical expertise, Novogene facilitates large-scale genomic studies and precision medicine initiatives through its network of high-capacity laboratories and integrated data management systems.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于北京诺禾致源科技股份有限公司2022年度募集资金存放与使用情况的专项核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from CITIC Securities regarding the 2022 annual special audit opinion on the deposit and use of raised funds by Beijing Nuohe Zhiyuan Technology Co., Ltd. It includes specific financial figures about the amount raised, usage, management, and compliance with regulatory requirements. The document references regulatory frameworks and includes a special audit opinion by the sponsor institution. The content focuses on the management and use of funds raised through an IPO, with detailed tables and explanations of fund usage, compliance, and audit conclusions. This matches the characteristics of an Audit Report / Information (AR), as it is a standalone audit opinion on a specific financial aspect (funds raised and their use), not a full annual report or earnings release. The document length (6424 characters) and detailed financial data support this classification rather than a simple announcement or regulatory filing. FY 2022
2023-04-12 Chinese
北京诺禾致源科技股份有限公司关于预计2023年度日常关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the company's expected related party transactions for the year 2023. It includes details about the nature of the transactions, approval procedures by the board and independent directors, estimated transaction amounts, related parties' information, and the impact on the company. It is not a full financial report but a regulatory announcement about related party transactions. The document is relatively short (4495 characters) and focuses on disclosure of expected related party transactions rather than financial results or management discussion. This fits the category of a Regulatory Filing (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2023-04-12 Chinese
北京诺禾致源科技股份有限公司独立董事关于第三届董事会第七次会议相关事项的事前认可意见
Regulatory Filings
2023-04-12 Chinese
北京诺禾致源科技股份有限公司独立董事关于第三届董事会第七次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on various board meeting agenda items, including the appointment of the 2023 audit firm, profit distribution plan for 2022, related party transactions, remuneration for directors and senior management, use of raised funds, cancellation of restricted stock, authorization for simplified stock issuance, cash management of idle funds, and asset impairment provisions. It references compliance with laws and regulations, audit firm qualifications, and internal governance procedures. The content is focused on board meeting matters and independent director opinions rather than full financial statements or detailed financial results. The document length is 2303 characters, which is relatively short and does not contain comprehensive financial data or full audit reports. This fits the category of Board/Management Information (MANG), as it relates to board meeting decisions and management-related approvals rather than a full audit report or annual report.
2023-04-12 Chinese
北京诺禾致源科技股份有限公司2022年年度审计委员会履职报告
Audit Report / Information Classification · 95% confidence The document is titled as the "2022 Annual Audit Committee Performance Report" of Beijing Novogene Bioinformatics Technology Co., Ltd. It details the composition of the audit committee, meetings held in 2022, their work including supervision of external audit, internal audit guidance, review of financial reports, internal control evaluation, and coordination between management and auditors. The document is a report by the audit committee on their activities and oversight for the year 2022. It is not the full annual report (10-K), nor is it a standalone audit opinion report (AR) in the strict sense, but rather a committee performance report related to audit activities. Given the content and nature, it fits best under Audit Report / Information (AR) category, which includes audit reports and related committee reports on audit activities, excluding full annual reports. The document length is 3215 characters, which is consistent with a detailed committee report rather than a brief announcement or certification. Therefore, the classification is AR with high confidence. FY 2022
2023-04-12 Chinese
北京诺禾致源科技股份有限公司2022年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as the "2022 年年度报告摘要" which translates to "2022 Annual Report Summary." It contains detailed financial data for the year 2022, including total assets, net profit, revenue, and other financial indicators. It also includes sections on company business overview, industry analysis, shareholder information, and risk disclosures. The length of the document (over 14,000 characters) and the presence of comprehensive financial and operational data indicate this is the actual annual report content, not just an announcement or summary notice. The document is not a certification, call transcript, or any other specific filing type. Therefore, it fits the definition of an Annual Report (10-K). FY 2022
2023-04-12 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.